| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.095 | 0.007 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.007 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.082 | 0.008 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.25 | 0.008 |
| mRNA | selumetinib:BRD-A02303741 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.01 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.085 | 0.01 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.12 | 0.01 |